Novartis rebuilds in Germany: Wehr closes, Halle grows
While 220 jobs are lost in Wehr, Novartis invests 35 million euros in Halle
Advertisement
Novartis has announced plans to close the production site in Wehr by the end of 2028. Solid oral dosage forms - tablets and capsules - for mainly established products from the Novartis portfolio are manufactured in Wehr using proven technologies. The site is no longer competitive.
The planned closure is expected to lead to the loss of around 220 jobs. All planned changes are now subject to statutory information and consultation procedures with the relevant employee representative bodies. Novartis is committed to managing the planned changes responsibly, transparently and in close cooperation with the Works Council, ensuring a socially responsible implementation.
"We are aware of the uncertainty that this announcement brings for our colleagues at the Wehr site. We will work closely, transparently and respectfully with our employees and the Wehr community throughout the process," said Steffen Lang, President Operations at Novartis. "We thank the team for their many years of dedication and the consistently high quality of their work."
Novartis has a strong presence in Germany, contributing to the supply of innovative medicines to patients. The planned closure in Wehr will have no impact on the supply of medicines to patients. The company remains clearly committed to Germany as a business location and will continue its involvement in research and development, particularly in the area of clinical trials, and its close cooperation with scientific and medical institutions and patient groups.
As part of a long-term commitment, Novartis is also focusing on the further development of innovative manufacturing technologies in Germany. As already announced in 2025, Novartis is investing EUR 35 million in a new production facility for radioligand therapies in Halle (Saxony-Anhalt). The planned site will manufacture innovative, personalized cancer therapies for patients in Germany and is scheduled to start operations in 2027.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
